Cuproptosis, a novel copper-driven cell death, offers potential for cancer therapy, yet challenges persist in targeted delivery of copper ions and therapeutic resistance management. Here, CuTG-Cas9@PLL, a cuproptosis nano-inducer for efficient delivery of Cu ions, 6-Thio-dG (6-thio-2 '-deoxyguanosine), and CRISPR/Cas9 to enhance cuproptosis and immunotherapy via telomere stress and metabolic interference is developed. This system, combined with microneedle patches for transdermal delivery in melanoma treatment, targets the "Warburg effect," a key resistance mechanism, through CRISPR/Cas9-media...